Clinical trial · no report yet · Phase 3
ADELA
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- NCT06382948 ↗
- Recruiting
- MedSIR
- 17 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 9 | |
| Podcasts | 6 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; ESR1 Gene Mutation
- Interventions
- Everolimus; Elacestrant; Placebo; Auxiliary Medicinal Product - Dexamethasone; Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
- Arms
- Interventional Arm 1 · Experimental
- Control Arm 2 · Active comparator
- Enrollment
- 300 (estimated)
- Primary outcomes
- To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).
- Sponsor
- MedSIR with Stemline Therapeutics, Inc.
- Start
- Dec 5, 2024
- Primary completion
- Sep 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06382948 · updated Aug 24, 2026